Vectura, Inspira team up to develop inhaled COVID-19 drug
The deal will see Vectura test Inspira’s inhaled IPX formulation candidates
Read More
Tag: Vectura
Vectura, Kinaset Therapeutics set to develop inhaled asthma drug
Companies have signed development and commercialisation agreement
Read More
Vectura wins patent litigation battle against GSK, awarded $89.7M
The companies had entered into an agreement in 2010 under which GSK had taken a license to formulation technology covered by a Vectura patent family.
Read More
Vectura pulls the plug on experimental asthma therapy
Vectura says it no longer plans to develop and partner experimental asthma therapy VR475, after it failed to hit Phase III targets.
Read More
Hikma, Vectura to develop generic rivals to GSK’s Ellipta portfolio
Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline’s Ellipta portfolio, utilising the latter’s Open-Inhale-Close dry powder inhaler device.
Read More
Vectura concludes paediatric asthma studies
Chippenham, UK-based Vectura says it has now successfully concluded two paediatric studies to support the potential use of asthma drug/device combo VR647.
Read More
Hikma/Vectura’s generic Advair delayed in the US
US regulators have upheld a prior decision rejecting Hikma and Vectura’s generic formulation of GlaxoSmithKline’s asthma and chronic obstructive pulmonary syndrome therapy Advair Diskus.
Read More
Vectura allows Dynavax access to smart inhalers
Vectura has signed an exclusive global agreement with Dynavax Technologies allowing use of its proprietary smart nebuliser technology to deliver an investigational immunotherapeutic to lung cancer patients.
Read More
Vectura links with Novartis for inhaled asthma/COPD generic
British drugmaker Vectura has signed an exclusive deal with Novartis unit Sandoz to develop a generic version of an existing major inhaled combination therapy for asthma and COPD in the US.
Read More
Setback for Vectura/Hikma’s Advair Diskus generic
Chippenham, UK-based Vectura and its partner Hikma Pharmaceuticals have announced a major setback in the US after VR315, a generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus, was rejected by the FDA.
Read More
Vectura trial gets green light for smart nebuliser trial
US regulators have given UK-based Vectura a green light to carry out a Phase I clinical trial of VR647, a drug/device combination being developed for paediatric asthma.
Read More
Mundipharma bags rights to Vectura’s novel respiratory therapy
Mundipharma has signed a deal with Vectura to develop and commercialise VR2076, a novel inhaled triple therapy in development for the treatment of asthma and COPD.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
